Effects of fluoxetine on fish: What do we know and where should we focus our efforts in the future?

被引:23
|
作者
Correia, Daniela [1 ]
Domingues, Ines [1 ]
Faria, Melissa [2 ]
Oliveira, Miguel [1 ]
机构
[1] Univ Aveiro, Ctr Environm & Marine Studies CESAM, Dept Biol, Campus Univ Santiago, P-3810193 Aveiro, Portugal
[2] IDAEA CSIC, Jordi Girona 18, Barcelona 08034, Spain
关键词
SSRIs; Antidepressants; Serotonin; Effects; Environmental levels; SEROTONIN REUPTAKE INHIBITORS; ZEBRAFISH DANIO-RERIO; PHARMACEUTICAL POLLUTANT FLUOXETINE; SOLID-PHASE EXTRACTION; ENVIRONMENTALLY-RELEVANT CONCENTRATIONS; WASTE-WATER CONTAMINANTS; TRAP MASS-SPECTROMETRY; PERSONAL CARE PRODUCTS; SIAMESE FIGHTING FISH; ANTIDEPRESSANT FLUOXETINE;
D O I
10.1016/j.scitotenv.2022.159486
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
Fluoxetine is one of the most studied and detected selective serotonin reuptake inhibitors in the aquatic environment, found at concentrations ranging from ng/L to mu g/L. Its presence in this environment can induce effects on aquatic or-ganisms that may compromise their fitness. Several experimental studies have demonstrated that fluoxetine can in-duce neurotoxicity, genetic and biochemical changes, and cause behavioral dysfunction in a wide range of fish species. However, contradictory results can be found. There is thus the need for a comprehensive review of the current state of knowledge on the effects of fluoxetine on fish at different levels of biological organization, highlighting inclu-sive patterns and discussing the potential causes for the contradictory results, that can be found in the available liter-ature. This review also aims to explore and identify the main gaps in knowledge and areas for future research. We conclude that environmentally relevant concentrations of fluoxetine (e.g., from 0.00345 mu g/L) produced adverse ef-fects and often this concentration range is not addressed in conventional environmental risk assessment strategies. Its environmental persistence and ionizable properties reinforce the need for standardized testing with representative aquatic models, targeting endpoints sensitive to the specific mode of action of fluoxetine, in order to assess and rank its actual environmental risk to aquatic ecosystems.
引用
收藏
页数:19
相关论文
共 22 条
  • [11] Presence of the Neurotoxin BMAA in Aquatic Ecosystems: What Do We Really Know?
    Faassen, Elisabeth J.
    TOXINS, 2014, 6 (03) : 1109 - 1138
  • [12] What do we know about carcinoid heart disease in the present era?
    Peczkowska, Mariola
    Konsek-Komorowska, Sonia J.
    Kolasinska-Cwikla, Agnieszka
    Konka, Marek
    Michalowska, Ilona
    Cwikla, Jaroslaw B.
    KARDIOLOGIA POLSKA, 2022, 80 (10) : 990 - 1001
  • [13] What do we know about the ecotoxicology of pharmaceutical and personal care product mixtures? A critical review
    Godoy, Aline A.
    Kummrow, Fabio
    CRITICAL REVIEWS IN ENVIRONMENTAL SCIENCE AND TECHNOLOGY, 2017, 47 (16) : 1453 - 1496
  • [14] We Don't Know What We Don't Study: The Case for Research on Medication Effects in Pregnancy
    Parisi, Melissa A.
    Spong, Catherine Y.
    Zajicek, Anne
    Guttmacher, Alan E.
    AMERICAN JOURNAL OF MEDICAL GENETICS PART C-SEMINARS IN MEDICAL GENETICS, 2011, 157C (03) : 247 - 250
  • [15] Stakeholder Approach: What Effects Should We Take into Account in Contemporary Societies?
    Jose Maria Lopez-De-Pedro
    Eva Rimbau-Gilabert
    Journal of Business Ethics, 2012, 107 : 147 - 158
  • [16] Stakeholder Approach: What Effects Should We Take into Account in Contemporary Societies?
    Maria Lopez-De-Pedro, Jose
    Rimbau-Gilabert, Eva
    JOURNAL OF BUSINESS ETHICS, 2012, 107 (02) : 147 - 158
  • [17] What do we know about long-term treatment outcomes for severe depressive disorders?
    Strawbridge, Rebecca
    Jaeckle, Tanja
    Cleare, Anthony J.
    BJPSYCH OPEN, 2020, 6 (02):
  • [18] A comprehensive review of various approaches for treatment of tertiary wastewater with emerging contaminants: what do we know?
    Zahmatkesh, Sasan
    Bokhari, Awais
    Karimian, Melika
    Zahra, Musaddak Maher Abdul
    Sillanpaa, Mika
    Panchal, Hitesh
    Alrubaie, Ali Jawad
    Rezakhani, Yousof
    ENVIRONMENTAL MONITORING AND ASSESSMENT, 2022, 194 (12)
  • [19] What do we know about the serotonergic genetic heterogeneity in attention-deficit/hyperactivity and autistic disorders?
    Sinzig, J.
    Lehmkuhl, G.
    PSYCHOPATHOLOGY, 2007, 40 (05) : 329 - 337
  • [20] What Do We Really Know About 5-HT1A Receptor Signaling in Neuronal Cells?
    Rojas, Paulina S.
    Fiedler, Jenny L.
    FRONTIERS IN CELLULAR NEUROSCIENCE, 2016, 10